These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 28864502)

  • 1. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
    Douros A; Yin H; Yu OHY; Filion KB; Azoulay L; Suissa S
    Diabetes Care; 2017 Nov; 40(11):1506-1513. PubMed ID: 28864502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study.
    Filion KB; Douros A; Azoulay L; Yin H; Yu OH; Suissa S
    Br J Clin Pharmacol; 2019 Oct; 85(10):2378-2389. PubMed ID: 31276600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic Heterogeneity and Risk of Severe Hypoglycemia with Concomitant Use of Sulfonylureas and DPP-4 Inhibitors: Population-Based Cohort Study.
    Dimakos J; Cui Y; Platt RW; Renoux C; Filion KB; Douros A
    Clin Pharmacol Ther; 2023 Sep; 114(3):712-720. PubMed ID: 37326010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Res Clin Pract; 2015 Jan; 107(1):104-12. PubMed ID: 25458330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality risk among sulfonylureas: a systematic review and network meta-analysis.
    Simpson SH; Lee J; Choi S; Vandermeer B; Abdelmoneim AS; Featherstone TR
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):43-51. PubMed ID: 25466239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes.
    Abdelmoneim AS; Eurich DT; Senthilselvan A; Qiu W; Simpson SH
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1186-1195. PubMed ID: 27102581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.
    Douros A; Dell'Aniello S; Yu OHY; Filion KB; Azoulay L; Suissa S
    BMJ; 2018 Jul; 362():k2693. PubMed ID: 30021781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS.
    Confederat L; Constantin S; Lupaşcu F; Pânzariu A; Hăncianu M; Profire L
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):579-84. PubMed ID: 26204670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Mitochondrial Adenosine Triphosphate-Sensitive Potassium Channel High- vs Low-Affinity Sulfonylureas and Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With Metformin.
    Wang MT; Pan HY; Huang YL; Wu LW; Wang PC; Hsu YJ; Lin TC; Lin C; Lai JH; Lee CH
    JAMA Netw Open; 2022 Dec; 5(12):e2245854. PubMed ID: 36484988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure.
    Andersson C; Gislason GH; Jørgensen CH; Hansen PR; Vaag A; Sørensen R; Mérie C; Olesen JB; Weeke P; Schmiegelow M; Norgaard ML; Køber L; Torp-Pedersen C
    Diabetes Res Clin Pract; 2011 Oct; 94(1):119-25. PubMed ID: 21831467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.
    Abdelmoneim AS; Eurich DT; Gamble JM; Johnson JA; Seubert JM; Qiu W; Simpson SH
    Diabetes Obes Metab; 2014 Jan; 16(1):22-9. PubMed ID: 23802997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
    Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
    Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rates of hypoglycemia in users of sulfonylureas.
    van Staa T; Abenhaim L; Monette J
    J Clin Epidemiol; 1997 Jun; 50(6):735-41. PubMed ID: 9250272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population-based cohort study.
    Douros A; Dell'Aniello S; Yu OHY; Suissa S
    Diabetes Obes Metab; 2020 Feb; 22(2):254-262. PubMed ID: 31596043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy.
    Wheeler S; Moore K; Forsberg CW; Riley K; Floyd JS; Smith NL; Boyko EJ
    Diabetologia; 2013 Sep; 56(9):1934-43. PubMed ID: 23797633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia.
    Yu O; Azoulay L; Yin H; Filion KB; Suissa S
    Am J Med; 2018 Mar; 131(3):317.e11-317.e22. PubMed ID: 29032229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative safety of sulfonylureas among U.S. nursing home residents.
    Zullo AR; Riester MR; Hayes KN; Munshi MN; Berry SD
    J Am Geriatr Soc; 2023 Apr; 71(4):1047-1057. PubMed ID: 36495141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus.
    Cho EH; Han K; Kim B; Lee DH
    Medicine (Baltimore); 2020 Jul; 99(29):e21236. PubMed ID: 32702900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia.
    Leonard CE; Brensinger CM; Aquilante CL; Bilker WB; Boudreau DM; Deo R; Flory JH; Gagne JJ; Mangaali MJ; Hennessy S
    Diabetes Care; 2018 Apr; 41(4):713-722. PubMed ID: 29437823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Specificity of Sulfonylureas to Cardiac Mitochondrial KATP Channels and the Risk of Major Adverse Cardiovascular Events in Type 2 Diabetes.
    Wang MT; Huang YL; Lai JH; Lee CH; Wang PC; Pan HY; Lin C; Liou JT; Hsu YJ
    Diabetes Care; 2022 May; 45(5):1276-1287. PubMed ID: 35294529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.